Testosterone prescriptions for women in the United States have risen sharply, while patients and doctors face growing questions over access, insurance coverage and the lack of an FDA-approved testosterone product specifically designed for women.

Prescriptions Nearly Triple

According to a new Reuters report, prescriptions for testosterone therapy among women nearly tripled between January 2023 and July 2026.

The treatment is increasingly being considered for women experiencing menopause-related low sexual desire. However, testosterone is not FDA-approved for use in women, and medical guidelines currently support its use for a limited condition known as hypoactive sexual desire disorder.

Patients Face Prescription and Cost Barriers

Despite growing demand, some women are reporting difficulties obtaining testosterone prescriptions. Pharmacies including Amazon and CVS have rejected some prescriptions, while insurance coverage remains limited.

Some patients have turned to compounded testosterone or male-formulated products at lower doses, creating additional questions around dosing, consistency and safety.

More than 30 clinical trials are examining potential uses of testosterone therapy in women, while companies are also developing formulations specifically designed for female patients.

FDA Review Could Shape Women's Health Treatment

The FDA is expected to examine evidence surrounding testosterone use in women at an upcoming public workshop.

The growing debate highlights a broader issue in women's healthcare: whether new treatments and formulations can receive stronger clinical evidence and regulatory approval as demand increases.

For millions of women experiencing menopause-related symptoms, the outcome could influence future treatment options, prescription access and insurance coverage across the U.S.